The headaches go on at Bolar Pharmaceutical. On Aug. 27, the generic-drug manufacturer announced a $40 million settlement with SmithKline Beecham over Bolar's manufacture and sale of a generic version of SmithKline's Dyazide blood-pressure medicine.
It was only the latest in a string of costly settlements for Bolar. Earlier this year, the company agreed to pay $23.8 million to settle Dyazide-related suits brought by drug buyers and shareholders. In March, it agreed to pay $10 million in fines and pleaded guilty to federal charges of distributing adulterated and misbranded drugs and obstructing federal investigations. The company's future now is unclear. Last year, it stopped producing just about all of its products.